Trials / Completed
CompletedNCT05392231
Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM
Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers Glycated Albumin and Insulin-regulated Aminopeptidase in Women With Gestational Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 109 (actual)
- Sponsor
- Haseki Training and Research Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Accepted
Summary
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).
Detailed description
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).In this prospective observational study including 109 pregnant women, the fetal pancreas size and maternal serum biomarkers GA and IRAP were measured at the gestational age of 20-22 weeks and later at the gestational age of 24-28 weeks, in 19 participants of them, GDM was confirmed with the 75-g oral glucose tolerance test (OGTT) and the fetal pancreas size was measured in all the participants again.
Conditions
Timeline
- Start date
- 2022-02-10
- Primary completion
- 2022-04-30
- Completion
- 2022-05-10
- First posted
- 2022-05-26
- Last updated
- 2022-06-01
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT05392231. Inclusion in this directory is not an endorsement.